Atezolizumab/bevacizumab is a first‐line therapy for unresectable hepatocellular carcinoma (HCC). Among several adverse events, grade ≥2 proteinuria is considered a significant adverse event that may cause bevacizumab interruption. Studies have… Click to show full abstract
Atezolizumab/bevacizumab is a first‐line therapy for unresectable hepatocellular carcinoma (HCC). Among several adverse events, grade ≥2 proteinuria is considered a significant adverse event that may cause bevacizumab interruption. Studies have shown that proteinuria might predict improved prognosis, although data are scarce and the association remains controversial, and the mechanisms and predictive factors remain unclear. We aimed to clarify these.
Keywords:
unresectable hepatocellular;
hepatocellular carcinoma;
bevacizumab;
improved prognosis;
atezolizumab bevacizumab
Journal Title: Hepatology Research
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hepatology Research
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!